India drugmaker stocks exception in Asian rout

Last Updated: Thursday, September 3, 2015, 08:14

Continued strength in the dollar when the Federal Reserve raises interest rates will also boost their income. More than 40 percent of over-the-counter and generic prescription drugs sold in the United States come from India.

Pharmexcil sees $1.2 billion export hit from EU ban

Last Updated: Monday, July 27, 2015, 18:39

India's business loss arising from the European Union's ban on 700 generic drugs is likely to be around USD 1.2 billion, says industry body Pharmexcil.

Focus on getting Ranbaxy's plants USFDA nod one at a time: Sun Pharma

Last Updated: Sunday, June 7, 2015, 14:41

The Mumbai-based drug major, which acquired Ranbaxy in a USD 4 billion deal, feels it is important for the merged entity to "re-establish" the trust between Ranbaxy and the US Food and Drug Administration (USFDA).

Drug makers' tax benefit claim on freebies, gifts unlawful: CAG

Last Updated: Sunday, May 10, 2015, 14:36

Slamming the practice of pharma companies offering freebies and gifts to doctors, government auditor CAG said that drug makers have claimed tax benefits on such expenses despite these being prohibited by law.

NPPA warns drug cos over non-registration with online database

Last Updated: Monday, May 4, 2015, 21:59

With just 41 out of top 100 pharma firms responding to its direction to register for online database, drug price regulator NPPA has warned to take action if the rest of the companies did not comply with its order immediately.

Pharma exports: FTP promises to address problems abroad

Last Updated: Thursday, April 2, 2015, 18:44

With Indian pharma companies facing problems in exports to countries like Japan and China, the new Foreign Trade Policy seeks to address issues related to non-trade barriers and regulations faced by them abroad.

Sun Pharma gets US FTC clearance for Ranbaxy acquisition

Last Updated: Monday, February 2, 2015, 11:14

The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition, it added.

Pharma in 2014: Deals worth billions and fines worth millions

Last Updated: Friday, December 26, 2014, 11:27

It's been a year of bitter medicine for Indian pharma companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including the high profile Sun-Ranbaxy merger.

Sun Pharma, Ranbaxy to sell 7 products to meet CCI conditions

Last Updated: Monday, December 8, 2014, 20:26

While approving their USD 4-billion merger, Competition Commission of India (CCI) has asked the two companies to divest seven products to address anti-competitive concerns.

CCI suggests changes to Sun Pharma-Ranbaxy deal

Last Updated: Monday, December 1, 2014, 15:56

The deal, which CCI has prima-facie found to be in violation of competition norms, was inked in April this year and has been awaiting clearance from the competition watchdog since then.